Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Weight-loss drugs like Ozempic are booming in popularity, but experts warn they aren't silver bullets for obesity.

Plus: The story behind the award-winning science that led to Ozempic, the next astronaut launch and why homework is good for ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

Patients taking GLP-1s had a 15-20% reduction in MACE (heart attack and stroke), which is consistent with clinical trials ...

China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster ...

Kourtney Kardashian’s supplement brand, Lemme has launched a natural weight loss aid. GLP-1 Daily is named for the active ...

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

It’s a brain disease,” a prominent obesity doctor explained on a “60 Minutes” episode about the drugs. “Obesity is disease” ...

Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...